As of July 27, 2024, Anglo French Drug & Industries, Unlisted Shares are trading at ₹1320.00 per share, with a 52-week high of ₹2580 and 52-week low of ₹1320. The minimun lot size is 120 shares, and the shares are traded on NSDL and CDSL.
ISIN
INE570E01016
An International Securities Identification Number (ISIN) is a code that uniquely identifies a specific securities issue. The numbers are allocated by a country's respective national numbering agency (NNA).
Face Value
₹ 10
Value of a security, as stated by its issuer. It has no relation with market price of the stock.
Total Share
12,91,000
Total shares or total number of shares outstanding represents the amount of stock on the open market, including shares held by institutional investors and restricted shares held by insiders and company officers.
Total Income
₹ 102.51 undefined
Gross income refers to the total income earned by an individual on a pay check before taxes and other deductions. It comprises all incomes received by an individual from all sources – including wages, rental income, interest income, and dividends.
Profit After Tax
₹ ****
It is the final profit left over after subtracting all operating and non operating items from net revenue.
EPS
₹ ****
It is the profit allocated to each outstanding share of common stock.
P/E
****
It is a valuation parameter that measures the company's current share price relative to its per-share earnings. Generally, high P/E is Overvalued & low P/E is Undervalued.
P/B
****
It shows the relationship between the current price and the book value of each share. A lower P/B ratio can mean that the stock is undervalued.
Market Capitalisation
₹ 170.41 Cr
Market capitalization is the aggregate valuation of the company based on its current share price and the total number of outstanding shares.
Enterprise Value
₹ ****
It measures companys total value, which includes market capitalization, debt and excludes cash.
Book Value
₹ 879.95
It calculates the per share value of a company based on its equity available to common shareholders
Intrinsic Value
₹ ****
Intrinsic value is the anticipated value of a company or stock determined through fundamental analysis. It is also referred to as the price a rational investor is willing to pay for an investment, given its level of risk.
Earnings Yield
111.97 %
Sector
Health Care
A sector is an area in which businesses share the same or a related product or service. It can also be known as an industry or market that shares common operating characteristics
Sub-sector
Pharmaceuticals
Subsectors are the divisions of a sector. They are areas that vary from the rest of the sector substantially enough to justify creating a plan just for the subsector.
Category
Listed on Small Exchange
Category is defined as a class or division of things regarded as having particular shared characteristics.
Cashflow - Operations
₹ 184.69
It indicates the amount of money a company brings in from its ongoing and regular operations over a fixed period of time.
Cashflow - Financing
-₹ 11.7
It shows the net flows of cash that are used to fund the company, which include transactions involving debt, equity, and dividends.
Anglo French Drugs & Industries Growth
Compounded Sales Growth
1 Year
4 Year
7 Year
Compounded Profit Growth
1 Year
3 Year
7 Year
Return On Equity
2017
2020
2023
Highlights
About the Company: Anglo French Drugs & Industries Ltd. ("AFDIL"), is primarily involved in the manufacturing of pharmaceutical formulation, which primarily involves mixing various chemical compounds into active drugs/ingredients. The company is the formulator, supplier, and distributor of drugs and medicines across nutraceuticals, CNS, skin, and respiratory segments. From being an importer of medicines in 1923, the company has emerged as the manufacturer, marketer, and distributor of over 350 products across the world; over 100 years
Revenue Growth: The company's revenue has experienced a substantial decrease, reducing from ₹165 crore in FY22 to ₹102 crore in FY23, indicating a negative growth rate of -38%. Over the past years, the company's revenue has consistently increased, unlike FY23, which has represented a decrease. The company has achieved a compound annual growth rate (CAGR) of -2% from FY18 to FY23.
Notable Investors: The company has some prominent names on the captable such as Life Insurance Corporation of India holds a 7% and Ninaad Finance & Properties holds a 10% stake in the company.
Investment Thesis: Despite being in operation for six decades, the company's annual revenue remains below ₹170 Crores, indicating a potential efficiency concern. While the company recorded a profit (PAT) of ₹190 Crores in FY23, it's crucial to note that this figure includes a one-time gain of ₹299.68 Crores from the sale of brands. Excluding this exceptional item, the company incurred an operational loss of ₹40 Crores, highlighting underlying financial challenges. This raises inquiries about the company's overall financial performance and its capacity to effectively overcome current obstacles.